Clinical Trial Update: Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia [Phase 1]

View source ↗

Summary

The update reports termination of a Phase 1 trial evaluating AHN-12, a Yttrium-90 labeled anti-CD45 monoclonal antibody, in advanced leukemia and myelodysplasti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• AHN-12 (Yttrium-90 labeled anti-CD45 monoclonal antibody) (AHN-12)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Leukemia, Myelodysplastic Syndromes | Phase 1 | Status: TERMINATED